Yesterday, attorneys at the firm filed the first testosterone treatment lawsuit on behalf of five men against Abbott Laboratoes and AbbVie, Inc.
The men range in age from 50 to 63 and have either experienced a heart attack, stroke or mini-stroke after they started using AndroGel, according to the complaint.
The litigation, filed in federal court in Chicago, comes just days after the U.S. Food & Drug Administration announced the launch of an investigation into the risks of testosterone treatment drugs. Recent medical studies have found that men who take testosterone therapy face an increased risk of suffering heart attack, stroke and even death.
Bloomberg reported on the testosterone treatment lawsuit. Read the full article here.
The cases are Aurecchia v. AbbVie Inc. (ABBV), 14-cv-00772; Benn v. AbbVie, 14-cv-00774; Gallagher v. AbbVie Inc., 14-cv-00776; Marino v. AbbVie Inc., 14-cv-00777 and Myers v. AbbVie Inc., 14-cv-00780, U.S. District Court, Northern District of Illinois (Chicago).
The law firm Morelli Alters Ratner LLP in New York is co-counsel.
